Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
LetterLetters

Different conclusions about memantine

Joel Lexchin
Canadian Family Physician March 2007; 53 (3) 403-404;
Joel Lexchin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

In the January issue of Canadian Family Physician, Dr Fadi Massoud was enthusiastic about the use of memantine in thetreatment ofmoderate to severeAlzheimer disease, calling it “effective and well tolerated.”1 In reaching this conclusion he cited 5 studies published between 1999 and 2004.2–6 Drug bulletins around the world and funding organizations in Canada and Australia looking at some or all of the same studies have reached markedly different conclusions than Dr Massoud has.

The Medical Letter noted that the drug “has been modestly effective in some US studies in improving performance.”7 The British Drug and Therapeutics Bulletin concluded that, at best, memantine produces only a small reduction in the rate of deterioration in global, functional, and cognitive scales among patients with moderately severe to severe disease.8 Moreover Drug and Therapeutics Bulletin could not find any evidence that treatment with memantine “reduces caregiver time and helps prevent institutionalization.” Prescrire International, the English-language translation of the French bulletin La revue Prescrire, said that data on the effects of memantine in patients with severe Alzheimer disease were sparse and weak. For moderately severe disease, Prescrire rated memantine a possible second-line option.9 The Therapeutics Letter published out of the University of British Columbia said that in advanced Alzheimer disease “memantine has not been demonstrated to improve outcomes of importance to patients and caregivers.”10

The Canadian Common Drug Review (CDR), which evaluates drugs for provincial and federal drug plans, did not recommend that the plans pay for memantine. Although 2 of 3 randomized controlled trials that the CDR assessed reported statistically significant improvements in activities of living and cognition, there was insufficient scientific evidence to establish the clinical importance of these small differences. A third trial found no significant benefit in functional, cognitive, behavioural, and global assessments.11 The Pharmaceutical Benefits Advisory Committee, which is Australia’s equivalent of the CDR, said that the government should not fund the drug because of uncertain clinical benefits and the resulting uncertain cost-effectiveness.12

In the face of these overwhelmingly negative opinions about memantine, it is hard to understand how Dr Massoud reached his conclusions. Finally, the article did not contain any statement about the presence or absence of any competing interests that Dr Massoud might have.

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    1. Massoud F
    . Maladie d’Alzheimer. Mise à jour en 2007. Can Fam Physician 2007;53:50-4.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Orgogozo JM,
    2. Rigaud AS,
    3. Stoffler A,
    4. Mobius HJ,
    5. Forette F
    . Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM300). Stroke 2002;33:1834-9.
    OpenUrlAbstract/FREE Full Text
    1. Reisberg B,
    2. Doody R,
    3. Stoffler A,
    4. Schmidt F,
    5. Ferris S,
    6. Mobius HJ
    . Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 2003;348:1333-41.
    OpenUrlCrossRefPubMed
    1. Tariot PN,
    2. Farlow MR,
    3. Grossberg GT,
    4. Graham SM,
    5. McDonald S,
    6. Gergel I
    . Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-24.
    OpenUrlCrossRefPubMed
    1. Wilcock G,
    2. Mobius HJ,
    3. Stoffler A
    . A double-blind, placebo-controlled multi-centre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002;17:297-305.
    OpenUrlCrossRefPubMed
  3. ↵
    1. Windblad B,
    2. Portis N
    . Memantine in severe dementia: results of the 9M-Best Study (benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-46.
    OpenUrlCrossRefPubMed
  4. ↵
    Memantine for Alzheimer’s disease. Med Lett Drugs Ther 2003;45:73-4.
    OpenUrlPubMed
  5. ↵
    Memantine for dementia? Drug Ther Bull 2003;41:73-6.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer’s disease. Prescrire Int 2003;12:203-5.
    OpenUrlPubMed
  7. ↵
    Drugs for Alzheimer’s disease. Ther Lett 2005;56:1-4.
    OpenUrl
  8. ↵
    Canadian Expert Drug Advisory Committee. CEDAC final recommendation on reconsideration and reasons for recommendation: memantine. Edmonton, Alta: Canadian Coordinating Office for Health Technology Assessment; 2005 [Accessed 2007 January 23]. Available from: http://www.cadth.ca/index.php/en/cdr/search?&status=complete&order_field=drug_name.
  9. ↵
    Pharmaceutical Benefits Advisory Committee. November 2004 PBAC outcomes—“subsequent” decisions not to recommend. Woden, Conn: Department of Health and Ageing; 2004 [Accessed 2007 January 23]. Available from: http://www.health.gov.au/internet/wcms/publishing.nsf/Content/pbacrec-nov04-neg2.
PreviousNext
Back to top

In this issue

Canadian Family Physician: 53 (3)
Canadian Family Physician
Vol. 53, Issue 3
1 Mar 2007
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Different conclusions about memantine
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Different conclusions about memantine
Joel Lexchin
Canadian Family Physician Mar 2007, 53 (3) 403-404;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
Different conclusions about memantine
Joel Lexchin
Canadian Family Physician Mar 2007, 53 (3) 403-404;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • References
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Correction
  • Long-term monitoring needed for lichen sclerosus
  • Private-public partnerships not a threat to Canada’s health care system
Show more Letters

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire